Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 72
Filter
Add more filters

Publication year range
1.
J Med Genet ; 60(12): 1218-1223, 2023 Nov 27.
Article in English | MEDLINE | ID: mdl-37460202

ABSTRACT

BACKGROUND: Cancer predisposition syndromes (CPSs) are responsible for at least 10% of cancer diagnoses in children and adolescents, most of which are not clinically recognised prior to cancer diagnosis. A variety of clinical screening guidelines are used in healthcare settings to help clinicians detect patients who have a higher likelihood of having a CPS. The McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) is an electronic health decision support tool that uses algorithms to help clinicians determine if a child/adolescent diagnosed with cancer should be referred to genetics for a CPS evaluation. METHODS: This study assessed MIPOGG's performance in identifying Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin (nevoid basal cell carcinoma) syndromes in a retrospective series of 84 children diagnosed with cancer and one of these four CPSs in Canadian hospitals over an 18-year period. RESULTS: MIPOGG detected 82 of 83 (98.8%) evaluable patients with any one of these four genetic conditions and demonstrated an appropriate rationale for suggesting CPS evaluation. When compared with syndrome-specific clinical screening criteria, MIPOGG's ability to correctly identify children with any of the four CPSs was equivalent to, or outperformed, existing clinical criteria respective to each CPS. CONCLUSION: This study adds evidence that MIPOGG is an appropriate tool for CPS screening in clinical practice. MIPOGG's strength is that it starts with a specific cancer diagnosis and incorporates criteria relevant for associated CPSs, making MIPOGG a more universally accessible diagnostic adjunct that does not require in-depth knowledge of each CPS.


Subject(s)
Decision Support Systems, Clinical , Neoplastic Syndromes, Hereditary , Child , Humans , Algorithms , Neoplastic Syndromes, Hereditary/diagnosis , Neoplastic Syndromes, Hereditary/genetics , Retrospective Studies
2.
Childs Nerv Syst ; 40(5): 1339-1347, 2024 May.
Article in English | MEDLINE | ID: mdl-38279985

ABSTRACT

BACKGROUND: Cerebellar mutism (CM) is characterized by a significant loss of speech in children following posterior fossa (PF) surgery. The biological origin of CM remains unclear and is the subject of ongoing debate. Significant recovery from CM is less likely than previously described despite rigorous multidisciplinary neuro-rehabilitational efforts. METHODS: A national multi-centered retrospective review of all children undergoing PF resection in four midsized Canadian academic pediatric institutions was undertaken. Patient, tumor and surgical factors associated with the post-operative development of CM were reviewed. Retrospective identification of PF surgery patients including those developing and those that did not (internal control). RESULTS: The study identified 258 patients across the 4 centers between 2010 and 2020 (mean age 6.73 years; 42.2% female). Overall, CM was experienced in 19.5% of patients (N = 50). Amongst children who developed CM histopathology included medulloblastoma (35.7%), pilocytic astrocytoma (32.6%) and ependymoma (17.1%). Intraoperative impression of adherence to the floor of the 4th ventricle was positive in 36.8%. Intraoperative abrupt changes in blood pressure and/or heart rate were identified in 19.4% and 17.8% of cases. The clinical resolution of CM was rated to be complete, significant resolution, slight improvement, no improvement and deterioration in 56.0%, 8.0%, 20.0%, 14.0% and 2.0%, respectively. In the cohort of children who experienced post-operative CM as compared to their no-CM counterpart, proportionally more tumors were felt to be adherent to the floor of the 4th ventricle (56.0% vs 49.5%), intraoperative extent of resection was a GTR (74% vs 68.8%) and changes in heart rate were noted (≥ 20% from baseline) (26.0% vs 15.9%). However, a multiple regression analysis identified only abrupt changes in HR (OR 5.97, CI (1.53, 23.1), p = 0.01) to be significantly associated with the development of post-operative CM. CONCLUSION: As a devastating surgical complication after posterior fossa tumor surgery with variable clinical course, identifying and understanding the operative cues and revising intraoperative plans that optimizes the child's neurooncological and clinical outcome are essential.


Subject(s)
Cerebellar Neoplasms , Infratentorial Neoplasms , Medulloblastoma , Mutism , Humans , Child , Female , Male , Retrospective Studies , Mutism/etiology , Postoperative Complications , Canada , Infratentorial Neoplasms/surgery , Medulloblastoma/surgery , Syndrome , Cerebellar Neoplasms/surgery
3.
Br J Cancer ; 129(2): 318-324, 2023 08.
Article in English | MEDLINE | ID: mdl-37165200

ABSTRACT

BACKGROUND: Studies to date have yielded inconclusive results as to whether maternal medical history during pregnancy, and a child's early-life medical history contribute to the development of childhood brain tumours (CBTs). This study examined associations between maternal and childhood medical history and the risk of CBTs. METHODS: The Childhood Brain Tumour Epidemiology Study of Ontario (CBREO) examined children 0-15 years of age with newly diagnosed CBTs from 1997 to 2003. Multivariable logistic regression analysis determined associations for prenatal medications and childhood medical history, adjusted for child's demographics, and maternal education. Analyses were stratified by histology. A latency period analysis was conducted using 12- and 24-month lead times. RESULTS: Maternal intake of immunosuppressants during the prenatal period was significantly associated with glial tumours (OR 2.73, 95% CI 1.17-6.39). Childhood intake of anti-epileptics was significantly associated with CBTs overall, after accounting for 12-month (OR 8.51, 95% CI 3.35-21.63) and 24-month (OR 6.04, 95% CI 2.06-17.70) lead time before diagnosis. No associations for other medications were found. CONCLUSIONS: This study underscores the need to examine potential carcinogenic effects of the medication classes highlighted and of the indication of medication use. Despite possible reverse causality, increased CBT surveillance for children with epilepsy might be warranted.


Subject(s)
Brain Neoplasms , Prenatal Exposure Delayed Effects , Child , Female , Pregnancy , Humans , Case-Control Studies , Ontario/epidemiology , Prenatal Exposure Delayed Effects/epidemiology , Family , Brain Neoplasms/epidemiology , Brain Neoplasms/etiology , Risk Factors
4.
Childs Nerv Syst ; 39(4): 887-894, 2023 04.
Article in English | MEDLINE | ID: mdl-36633680

ABSTRACT

PURPOSE: To determine whether intraoperative adjunctive EVD placement in patients with a posterior fossa tumor (PFT) led to improved surgical, radiographic, and clinical outcomes compared to those who did not receive an EVD. METHODS: Patients were grouped as those who underwent routine intraoperative adjunctive EVD insertion and those who did not at time of PFT resection. Patients who pre-operatively required a clinically indicated EVD insertion were excluded. Comparative analyses between both groups were conducted to evaluate clinical, radiological, and pathological outcomes. Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were computed for post-operative outcomes. RESULTS: Fifty-five selected patients were included, 15 who had an EVD placed at the time of PFT resection surgery, and 40 who did not. Children without an EVD did not experience a higher rate of complications or poorer post-operative outcomes compared to those with an EVD placed during resection surgery. There was no significant difference in the degree of gross total resection (p = 0.129), post-operative CSF leak (p = 1.000), and post-operative hemorrhage (p = 0.554) between those with an EVD and those without. The frequency of new cranial nerve deficits post-operatively was higher in those with an EVD (40%) compared to those without (3%, p = 0.001). There was a trend towards more frequently observed post-operative hydrocephalus in the EVD group (p = 0.057). CONCLUSION: The routine use of EVD as an intraoperative adjunct in clinically stable pediatric patients with posterior fossa tumors and hydrocephalus may not be associated with improved radiological or clinical outcomes.


Subject(s)
Brain Neoplasms , Hydrocephalus , Infratentorial Neoplasms , Humans , Child , Retrospective Studies , Ventriculostomy/adverse effects , Postoperative Complications/etiology , Brain Neoplasms/surgery , Infratentorial Neoplasms/complications , Infratentorial Neoplasms/diagnostic imaging , Infratentorial Neoplasms/surgery , Hydrocephalus/etiology , Hydrocephalus/surgery , Drainage/adverse effects
5.
J Strength Cond Res ; 37(9): e527-e534, 2023 Sep 01.
Article in English | MEDLINE | ID: mdl-37184969

ABSTRACT

ABSTRACT: Fleming, A, Walker, M, Armitage, M, Connor, M, and Beato, M. A comparison of training and match play external load during a congested in-season period in English League 2 Football. J Strength Cond Res 37(9): e527-e534, 2023-This study aimed to investigate if external training load metrics differ between training days and match day (MD) during a period of fixture congestion and to verify if external load metrics vary based on playing positions. Training and MD data were collected in a part of the competition phase of the 2020-2021 season (6 weeks) in the English Football League 2 ( N = 20 players, mean ± SD s: age = 24.4 ± 4.7 years). Global Navigation Satellite System units (Catapult S7 Vector 10 Hz) were used to monitor external load metrics. The metrics were duration of training, total distance (TD), high-speed running distance (HSR), sprinting distance, relative intensity (m/min), total accelerations (TotAcc) (>3 m·s -2 ), and total decelerations (TotDec) (<-3 m·s -2 ). This study found that duration, TD, relative intensity, HSR distance, sprint distance, TotAcc, and TotDec were different ( p < 0.001, d = small to moderate ) between MD and match day minus two (MD-2) or match day minus one (MD-1); however, during match day minus four (MD-4), only relative intensity was significantly lower ( p < 0.001) compared with MD output. Therefore, MD-4 was the most demanding training session of the week (after the MD), and during MD-2 and MD-1, coaches decreased players' load to favor players' readiness. Moreover, this study found that MD and MD-1 resulted in statistically different values across several metrics between different playing positions (defenders < midfielders and strikers), whereas metrics in MD-4 and MD-2 were not statistically different, which highlights that in these sessions, players have similar external loads independently from their playing positions.


Subject(s)
Athletic Performance , Running , Soccer , Humans , Young Adult , Adult , Seasons , Geographic Information Systems
6.
Int J Cancer ; 150(5): 795-801, 2022 03 01.
Article in English | MEDLINE | ID: mdl-34520575

ABSTRACT

Head trauma in early childhood has been hypothesized as a potential risk factor for childhood brain tumours (CBTs). However, head trauma has not been extensively studied in the context of CBTs and existing studies have yielded conflicting results. A population-based and hospital-based case-control study of children 0 to 15 years with newly diagnosed CBTs from 1997 to 2003 recruited across Ontario through paediatric oncology centres was conducted. Controls were frequency-matched with cases by age, sex and geographical region. The association was assessed based on multivariable logistic regressions, accounting for child's age, sex, ethnicity, highest level of maternal education and maternal pack-years of smoking during the pregnancy. Analyses were conducted separately based on age of first head trauma, sex and histology. A latency period analysis was conducted. Overall, based on 280 cases and 919 controls, CBTs were not significantly associated with previous history of head trauma (OR 1.34, 95% CI 0.96, 1.86), head trauma severity, number of head injuries, or head or neck X-rays or computed tomography (CT) examinations. Results were consistent across sexes and histological subtypes. However, head trauma within the first year of life was significantly associated with CBTs (OR 2.00, 95% CI 1.01, 3.98), but the association diminished when adjusted for X-ray or CT occurring during the same time period (OR 1.62, 95% CI 0.75, 3.49), albeit limited sample size. Overall, no association was observed between head trauma and CBTs among all children, while head trauma occurring within first year of life may warrant further investigation in future research.


Subject(s)
Brain Neoplasms/etiology , Craniocerebral Trauma/complications , Case-Control Studies , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Logistic Models , Male , Risk Factors
7.
Am J Physiol Regul Integr Comp Physiol ; 323(5): R763-R775, 2022 11 01.
Article in English | MEDLINE | ID: mdl-36189990

ABSTRACT

Migration of monocytes-macrophages plays an important role in phagocytosis of pathogens and cellular debris in a variety of pathophysiological conditions. Although epithelial Na+ channels (ENaCs) are required for normal migratory responses in other cell types, their role in macrophage migration signaling is unknown. To address this possibility, we determined whether ENaC message is present in several peripheral blood monocyte cell populations and tissue-resident macrophages in healthy humans using the Human Protein Atlas database (www.proteinatlas.org) and the mouse monocyte cell line RAW 264.7 using RT-PCR. We then determined that selective ENaC inhibition with amiloride inhibited chemotactic migration (∼50%), but not phagocytosis, of the mouse monocyte-macrophage cell line RAW 264.7. Furthermore, we generated a cell line stably expressing an NH2-terminal truncated αENaC to interrupt normal channel trafficking and found it suppressed migration. Prolonged exposure (48 h) of RAW 264.7 cells to proinflammatory cytokines interferon γ (IFNγ) and/or tumor necrosis factor α (TNFα) inhibited RAW 264.7 migration and abolished the amiloride (1 µM)-sensitive component of migration, a finding consistent with ENaC downregulation. To determine if proinflammatory cytokines regulate αENaC protein expression, cells were exposed to proinflammatory cytokines IFNγ (10 ng/mL, last 48 h) and TNFα (10 ng/mL, last 24 h). By Western blot analysis, we found whole cell αENaC protein is reduced ≥50%. Immunofluorescence demonstrated heterogeneous αENaC inhibition. Finally, we found that overnight exposure to amiloride stimulated morphological changes and increased polarization marker expression. Our findings suggest that ENaC may be a critical molecule in macrophage migration and polarization.


Subject(s)
Epithelial Sodium Channels , Tumor Necrosis Factor-alpha , Mice , Animals , Humans , Epithelial Sodium Channels/genetics , Epithelial Sodium Channels/metabolism , Tumor Necrosis Factor-alpha/metabolism , Amiloride/pharmacology , Interferon-gamma/pharmacology , Interferon-gamma/metabolism , Cytokines/metabolism , Macrophages/metabolism
8.
J Pediatr Hematol Oncol ; 44(2): e479-e481, 2022 Mar 01.
Article in English | MEDLINE | ID: mdl-34486563

ABSTRACT

BACKGROUND: Frosted branch angiitis (FBA) is a rare phenomenon of panuveitis which may occur secondary to cytomegalovirus (CMV) causing acute visual disturbances. CMV infection is a known complication in allogenic stem cell transplant (SCT) patients but is uncommon following autologous SCT. OBSERVATION: We describe a 17-month-old medulloblastoma patient with sudden onset visual impairment following second autologous SCT. The patient was CMV seropositive, polymerase chain reaction negative before second SCT. At the time of presentation with visual complaints, the patient was diagnosed with FBA associated with CMV reactivation. Treatment included antivirals and immunosuppressive medication with visual recovery. CONCLUSION: FBA induced by CMV should be considered as a differential diagnosis in pediatric patients undergoing autologous bone marrow transplant with rapidly progressive visual impairment.


Subject(s)
Cytomegalovirus Infections , Hematopoietic Stem Cell Transplantation , Vasculitis , Child , Cytomegalovirus , Cytomegalovirus Infections/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Infant , Vasculitis/complications , Vasculitis/diagnosis , Vision Disorders/complications
9.
Pediatr Hematol Oncol ; 39(4): 291-303, 2022 May.
Article in English | MEDLINE | ID: mdl-34693863

ABSTRACT

Childhood and adolescent brain tumor survivors are at risk for long-term consequences of therapy. We reviewed adherence to long-term follow-up (LTFU) guidelines, assessed provider perspectives, and studied the needs, experience and quality of life (QOL) of pediatric malignant brain tumor survivors in the McMaster Children's Hospital Neuro-Oncology clinic. LTFU areas for improvement were evaluated using an anonymous health provider needs assessment questionnaire. The Cancer Care Experience Questionnaire (CCEQ), Cancer Worry Scale (CWS), Self-Management Skills Scale (SMSS), and PedsQL measured parents/patients' needs and QOL. Individual care plans were based on the Children's Oncology Group (COG) LTFU guidelines. Based on 17 responses, staff perceived areas for improvement included: increased multi-disciplinary participation, improved patient education and increased surveillance for therapy-related late effects. Thirty-two families participated, most felt they received high-quality care. Mean cancer worry scores were low (71.8 (± 28.4)). Survivors reported limited self-management skills (58.5 (±18.2)), requiring support with medical needs and activities of daily living. Overall median QOL scores were 'good' (parental report 72.3 (±17.7), survivor 68.2 (±16.6)). Utilizing survivorship guidelines and assessments from patients, caregivers and health providers, we implemented improvements in our provision of neuro-oncology survivorship care. Lessons learned may assist other LTFU programs.


Subject(s)
Brain Neoplasms , Neoplasms , Activities of Daily Living , Adolescent , Brain Neoplasms/therapy , Child , Delivery of Health Care , Disease Progression , Humans , Neoplasms/therapy , Quality of Life , Survivors
10.
Cancer Metastasis Rev ; 39(1): 79-90, 2020 03.
Article in English | MEDLINE | ID: mdl-31993840

ABSTRACT

Most children are surviving acute lymphoblastic leukemia (ALL) today. Yet, the emergence of cardiometabolic comorbidities in this population may impact long-term outcomes including the quality of life and lifespan. Obesity is a major driver of cardiometabolic disorders in the general population, and in ALL patients it is associated with increased risk of hypertension, dysglycemia, and febrile neutropenia when compared with lean ALL patients undergoing therapy. This systematic review aims to assess the current evidence for bariatric interventions to manage obesity in children with ALL. The primary outcome for this systematic review was the change in BMI z-score with implementation of the interventions studied. Literature searches were conducted in several databases. Ten publications addressing the study question were included in this review, and five studies were used in the meta-analysis to assess the impact of the bariatric interventions on obesity. The BMI z-score did not change significantly with the interventions. However, the quality of evidence was low, which precluded the recommendation of their use. In conclusion, prospective, rigorous, adequately powered, and high-quality longitudinal studies are urgently needed to deliver effective lifestyle interventions to children with ALL to treat and prevent obesity. These interventions, if successful, may improves cardiometabolic health outcomes and enhance the quality of life and life expectancy in children with ALL.


Subject(s)
Diet, Reducing , Exercise , Obesity/complications , Obesity/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Bariatric Surgery , Bariatrics/methods , Child , Humans , Life Style , Obesity/surgery , Randomized Controlled Trials as Topic
11.
J Pathol ; 251(3): 249-261, 2020 07.
Article in English | MEDLINE | ID: mdl-32391583

ABSTRACT

Central nervous system (CNS) tumors are the most common solid tumor in pediatrics, accounting for approximately 25% of all childhood cancers, and the second most common pediatric malignancy after leukemia. CNS tumors can be associated with significant morbidity, even those classified as low grade. Mortality from CNS tumors is disproportionately high compared to other childhood malignancies, although surgery, radiation, and chemotherapy have improved outcomes in these patients over the last few decades. Current therapeutic strategies lead to a high risk of side effects, especially in young children. Pediatric brain tumor survivors have unique sequelae compared to age-matched patients who survived other malignancies. They are at greater risk of significant impairment in cognitive, neurological, endocrine, social, and emotional domains, depending on the location and type of the CNS tumor. Next-generation genomics have shed light on the broad molecular heterogeneity of pediatric brain tumors and have identified important genes and signaling pathways that serve to drive tumor proliferation. This insight has impacted the research field by providing potential therapeutic targets for these diseases. In this review, we highlight recent progress in understanding the molecular basis of common pediatric brain tumors, specifically low-grade glioma, high-grade glioma, ependymoma, embryonal tumors, and atypical teratoid/rhabdoid tumor (ATRT). © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


Subject(s)
Biomarkers, Tumor/genetics , Brain Neoplasms/genetics , Cerebellar Neoplasms/genetics , Ependymoma/genetics , Glioma/genetics , Medulloblastoma/genetics , Rhabdoid Tumor/genetics , Teratoma/genetics , Age of Onset , Brain Neoplasms/classification , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Cerebellar Neoplasms/classification , Cerebellar Neoplasms/mortality , Cerebellar Neoplasms/pathology , Ependymoma/classification , Ependymoma/mortality , Ependymoma/pathology , Genetic Predisposition to Disease , Glioma/classification , Glioma/mortality , Glioma/pathology , Humans , Medulloblastoma/classification , Medulloblastoma/mortality , Medulloblastoma/pathology , Neoplasm Grading , Phenotype , Rhabdoid Tumor/classification , Rhabdoid Tumor/mortality , Rhabdoid Tumor/pathology , Teratoma/classification , Teratoma/mortality , Teratoma/pathology
12.
J Sports Sci ; 39(5): 482-488, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33019900

ABSTRACT

The aims of this study were to examine the test-retest reliability and construct validity of the flywheel (FW)-squat test. Twenty male amateur team sports athletes (mean±SD: age 23±3 years) completed one familiarization session and two testing sessions including: FW-squat test with an inertial load of 0.061 kg.m2, standing long jump (SLJ), countermovement jump (CMJ) and 5-m change of direction (COD-5m) tests, and isokinetic strength assessments of the knee extensor and flexor muscles. Test-retest reliability was assessed with intraclass correlation coefficient (ICC) and coefficient of variation (CV) of data collected. Construct validity was determined as the degree of relationships between the FW-squat test outputs and both athletic tests and isokinetic assessments scores computed with Pearson's correlation coefficients. Excellent relative (ICC=0.94-0.95) and acceptable absolute (CV=5.9%-6.8%) reliability scores were found for both concentric and eccentric power outputs collected during the FW-squat test. The same outputs showed moderate to large positive correlations with concentric and eccentric knee extensor and flexor muscle peak force values (r range: 0.465-0.566) measured during the isokinetic test. The FW-squat test is a valid and reliable test to assess lower limb performance given its correlation with isokinetic test, as well as its excellent relative and acceptable absolute reliability.


Subject(s)
Athletes , Exercise Test/instrumentation , Exercise Test/standards , Lower Extremity/physiology , Muscle Strength/physiology , Adult , Humans , Male , Reproducibility of Results , Young Adult
13.
J Neurooncol ; 149(1): 45-54, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32632896

ABSTRACT

BACKGROUND: Diffuse intrinsic pontine gliomas (DIPG) are midline gliomas that arise from the pons and the majority are lethal within a few months after diagnosis. Due to the lack of histological diagnosis the epidemiology of DIPG is not completely understood. The aim of this report is to provide population-based data to characterize the descriptive epidemiology of this condition in Canadian children. PATIENTS AND METHODS: A national retrospective study of children and adolescents diagnosed with DIPG between 2000 and 2010 was undertaken. All cases underwent central review to determine clinical and radiological diagnostic characteristics. Crude incidence figures were calculated using age-adjusted (0-17 year) population data from Statistics Canada. Survival analyses were performed using the Kaplan-Meier method. RESULTS: A total of 163 patients with pontine lesions were identified. Central review determined one-hundred and forty-three patients who met clinical, radiological and/or histological criteria for diagnosis. We estimate an incidence rate of 1.9 DIPG/1,000,000 children/year in the Canadian population over a 10 years period. Median age at diagnosis was 6.8 years and 50.3% of patients were female. Most patients presented with cranial nerve palsies (76%) and ataxia (66%). Despite typical clinical and radiological characteristics, histological confirmation reported three lesions to be low-grade gliomas and three were diagnosed as CNS embryonal tumor not otherwise specified (NOS). CONCLUSIONS: Our study highlights the challenges associated with epidemiology studies on DIPG and the importance of central review for incidence rate estimations. It emphasizes that tissue biopsies are required for accurate histological and molecular diagnosis in patients presenting with pontine lesions and reinforces the limitations of radiological and clinical diagnosis in DIPG. Likewise, it underscores the urgent need to increase the availability and accessibility to clinical trials.


Subject(s)
Brain Stem Neoplasms/therapy , Chemoradiotherapy/mortality , Diffuse Intrinsic Pontine Glioma/therapy , Adolescent , Brain Stem Neoplasms/epidemiology , Brain Stem Neoplasms/pathology , Canada/epidemiology , Child , Child, Preschool , Diffuse Intrinsic Pontine Glioma/epidemiology , Diffuse Intrinsic Pontine Glioma/pathology , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Male , Prognosis , Retrospective Studies , Survival Rate , Time Factors
14.
Pediatr Blood Cancer ; 67(1): e28041, 2020 01.
Article in English | MEDLINE | ID: mdl-31612572

ABSTRACT

BACKGROUND: Postoperative length of stay (LOS) carries a high burden of healthcare costs. In resource-intense specialties such as neurosurgery, it is imperative to identify factors that influence LOS to improve care. The current study investigates the potential for variables that affect clinical presentation, tumor characteristics, treatment modalities, and postoperative complications to impact overall LOS in pediatric brain tumor patients. METHODS: A retrospective cohort study design was used with patients enrolled in the McMaster Pediatric Brain Tumor Study Group database. All patients up to 18 years of age, presenting with a newly diagnosed brain tumor admitted to and discharged from neurosurgery, were included. Patients were sorted into three cohorts: short LOS (≤3 days), extended LOS (≥20 days), and control LOS (4-19 days). RESULTS: Of the 124 patients included, 20 (65% male; median age: 9.1 years; range, 0.8-17.4 years) were considered short LOS, 28 (61% male; median age: 4.7 years; range, 0.4-14.7 years) were considered extended LOS, and 76 (57% male; median age: 8.5 years; range, 0.3-17.9 years) were considered control LOS. Variables that prolonged LOS were emesis at presentation (P < 0.001), developmental delay (P = 0.02), multiple surgeries (P = 0.004), tumor location (P < 0.05), subtotal resection (P = 0.02), feeding tube (P < 0.001), adjuvant chemoradiotherapy (P < 0.001), and posterior fossa syndrome (P = 0.004). CONCLUSIONS: This study identifies variables related to clinical presentation, tumor characteristics, treatment modalities, and postoperative complications associated with extended LOS. These findings uncover novel predictors of LOS that can be used to guide future research and improve health resource management.


Subject(s)
Brain Neoplasms/surgery , Length of Stay/statistics & numerical data , Neurosurgical Procedures/standards , Postoperative Complications , Adolescent , Brain Neoplasms/pathology , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Male , Prognosis , Retrospective Studies , Risk Factors
15.
Pediatr Blood Cancer ; 66(3): e27540, 2019 03.
Article in English | MEDLINE | ID: mdl-30393943

ABSTRACT

Combining mammalian target of rapamycin (mTOR) inhibitors and vinca alkaloids has shown therapeutic synergy in xenograft models of pediatric cancers. This phase I study assessed safety and toxicity of temsirolimus in combination with vinblastine in children. PROCEDURE: Patients ≥ 1 and ≤ 18 years with recurrent/refractory solid or CNS tumors were eligible. Vinblastine (4 mg/m2 ) and temsirolimus (15 mg/m2 ) were administered i.v. weekly, with planned dose escalation of vinblastine using a rolling six phase I design. Pharmacokinetic and pharmacodynamic data were collected. RESULTS: Seven patients with median age 12 years (range, 8-18 years) were enrolled; all were evaluable for toxicity and six for response. At dose level 1, four of six patients developed grade 3 mucositis, of which one met duration criteria for dose-limiting toxicity (DLT). Four patients required dose omissions for grade 3 or 4 hematologic toxicity, including one prolonged neutropenia DLT. A subsequent patient was enrolled on dose level -2 (temsirolimus 10 mg/m2 , vinblastine 4 mg/m2 ) with no protocol-related toxicity > grade 1, except grade 2 neutropenia. Two serious adverse events (SAE) occurred-an allergic reaction to temsirolimus (grade 2) and an intracranial hemorrhage in a CNS tumor patient (grade 3)-unlikely related to study therapy. Soluble VEGFR2 was reduced at cycle 1, day 36 in keeping with inhibition of angiogenesis. Four patients achieved prolonged stable disease for a median of 5.0 months (range, 3.1-8.3 months). CONCLUSION: The combination of weekly temsirolimus (15 mg/m2 ) and vinblastine (4 mg/m2 ) exceeds the maximum tolerated dose in children, with frequent oral mucositis and hematologic toxicity.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Resistance, Neoplasm , Neoplasm Recurrence, Local/drug therapy , Neoplasms/drug therapy , Salvage Therapy , Adolescent , Canada , Child , Female , Follow-Up Studies , Humans , Male , Maximum Tolerated Dose , Neoplasm Recurrence, Local/pathology , Neoplasms/pathology , Prognosis , Sirolimus/administration & dosage , Sirolimus/analogs & derivatives , Survival Rate , Vinblastine/administration & dosage
16.
Can J Neurol Sci ; 46(4): 403-414, 2019 07.
Article in English | MEDLINE | ID: mdl-31293232

ABSTRACT

INTRODUCTION: Children diagnosed with medulloblastoma (MB) who are refractory to upfront therapy or experience recurrence have very poor prognoses. Although phase I and phase II trials exist, these treatments bear significant treatment-related morbidity and mortality. METHODS: A retrospective review of children diagnosed with a recurrence of MB from 2002 to 2015 at McMaster University was undertaken. RESULTS: Recurrent disease in 10 patients involved leptomeningeal dissemination, with 3 experiencing local recurrence. In three recurrent patients the disease significantly progressed, and the children were palliated. The remaining 10 children underwent some form of salvage therapy, including surgical re-resection, radiation, and chemotherapy, either in isolation or in varying combinations. Of the 13 children experiencing treatment-refractory or recurrent disease, 4 are currently alive with a median follow-up of 38.5 months (75.5 months). Of the eight patients with molecular subgrouping data, none of the Wnt MB experienced recurrence. CONCLUSION: Recurrent MB carried a poor prognosis with a 5-year overall survival (OS) of 18.2% despite the administration of salvage therapy. The upfront therapy received, available treatment, and tolerability of the proposed salvage therapy resulted in significant heterogeneity in the treatment of our recurrent cohort.


Traitement de sauvetage dans le cas du médulloblastome chez l'enfant : une expérience menée au sein d'un établissement hospitalier. Introduction: Les enfants chez qui l'on a diagnostiqué un médulloblastome réfractaire à un traitement initial ou qui sont victimes d'une récidive présentent d'habitude des pronostics de guérison vraiment défavorables. Bien qu'il existe des traitements basés sur des essais cliniques de phases I et II, ces traitements ont tendance à produire des taux notables de morbidité et de mortalité. Méthodes: Nous avons ainsi mené à l'Université McMaster une analyse rétrospective des dossiers d'enfants chez qui l'on avait diagnostiqué entre 2002 et 2015 une récidive de médulloblastome. Résultats: La réapparition de cette maladie chez 10 patients a provoqué un phénomène de diffusion leptoméningée, trois d'entre eux étant victimes d'une récidive locale. Sur ces 10 jeunes patients, la maladie a progressé de façon importante : ces enfants ont alors été transférés aux soins palliatifs. Quant aux autres 10 enfants, ils ont subi un certain type de traitement de sauvetage (des résections chirurgicales, de la radiothérapie, de la chimiothérapie), que ce soit de façon exclusive ou en variant les combinaisons possibles. Sur les 13 enfants réfractaires à un traitement initial ou victimes d'une récidive, 4 sont toujours en vie, leur suivi médian ayant été de 38,5 mois (75,5 mois). Sur les 8 patients pour qui on a pu obtenir des données moléculaires, aucun de ceux qui étaient atteints d'un médulloblastome du sous-type Wnt n'a connu de récidive. Conclusion: Les médulloblastomes qui réapparaissent après une période de guérison complète présentent un pronostic de guérison défavorable. Leur taux de survie globale est en effet de 18,2 % au cours d'une période de 5 ans, et ce, même après avoir bénéficié d'un traitement de sauvetage. Ajoutons aussi que le type de traitement initial reçu, la disponibilité des traitements ainsi que la tolérance à l'égard des traitements de sauvetage proposés a entraîné une grande hétérogénéité dans le traitement de ces jeunes patients victimes d'une récidive.


Subject(s)
Cerebellar Neoplasms/therapy , Medulloblastoma/therapy , Neoplasm Recurrence, Local/therapy , Salvage Therapy/methods , Adolescent , Cerebellar Neoplasms/mortality , Child , Child, Preschool , Female , Humans , Infant , Male , Medulloblastoma/mortality , Neoplasm Recurrence, Local/mortality , Retrospective Studies , Salvage Therapy/mortality , Treatment Outcome
18.
J Pediatr Hematol Oncol ; 40(3): e159-e163, 2018 04.
Article in English | MEDLINE | ID: mdl-29432312

ABSTRACT

Medulloblastoma is the most common malignant brain tumor in children. Published survival rates for this tumor are ∼70%; however, there is limited published information on outcome after disease recurrence. This was an observational study which included all persons under the age of 18 years diagnosed with medulloblastoma from 1990 to 2009 inclusive in Canada. Data collected included date of diagnosis, age at diagnosis, sex, stage, pathology, treatment, recurrence, and current status. Survival rates were determined. In total, 550 cases were ascertained meeting the study criteria. The overall survival rate at 1 year was 83.6%±1.7%, at 3 years 77.2%±1.9%, and at 5 years 72.5%±20%. The progression-free survival rates were 78%±1.9%, 70%±2.1%, and 69±2.1% at 1, 3, and 5 years from initial diagnosis. In total, 173 (31.2%) were reported to have had tumor recurrence and 23 (11.4%) of them were alive at the time of survey with an overall survival rate at 1 year of 38.3%±4%, at 2 years of 16.9%±3.3%, and at 5 years of 12.4%±2.8%. Our data confirm that children with recurrent medulloblastoma have a poor prognosis, supporting the need for novel treatment approaches for this group.


Subject(s)
Cerebellar Neoplasms/mortality , Medulloblastoma/mortality , Neoplasm Recurrence, Local/mortality , Adolescent , Canada/epidemiology , Child , Child, Preschool , Female , Humans , Infant , Male
19.
J Neurooncol ; 133(3): 539-552, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28527006

ABSTRACT

The surgical risk factors and neuro-imaging characteristics associated with cerebellar mutism (CM) remain unclear and require further investigation. Therefore, we aimed to examine surgical and MRI findings associated with CM in children following posterior fossa tumor resection. Using our data registry, we retrospectively collected data from pediatric patients who acquired CM and were matched based on age and pathology type with individuals who did not acquire CM after posterior fossa surgery. The strength of association between surgical and MRI variables and CM were examined using odds ratios (ORs) and corresponding 95% confidence intervals (CIs). A total of 22 patients (11 with and 11 without CM) were included. Medulloblastoma was the most common pathology among CM patients (91%); the remaining 9% were diagnosed with a pilocytic astrocytoma. Tumor attachment to the floor of the fourth ventricle (OR 6; 95% CI 0.7-276), calcification/hemosiderin deposition (OR 7; 95% CI 0.9-315.5), and post-operative peri-ventricular ischemia on MRI (OR 5; 95% CI 0.5-236.5) were found to have the highest measures of association with CM. Our results may suggest that tumor attachment to the floor of the fourth ventricle, pathological calcification, and post-operative ischemia have a relatively higher prevalence in patients with CM. Collectively, our work calls for a larger multi-institutional cohort study of CM patients to encourage further investigation of the determinants and management of CM in order to potentially minimize its development and predict onset.


Subject(s)
Cerebellar Diseases/diagnostic imaging , Cerebellar Diseases/etiology , Infratentorial Neoplasms/diagnostic imaging , Infratentorial Neoplasms/surgery , Mutism/diagnostic imaging , Mutism/etiology , Astrocytoma/diagnostic imaging , Astrocytoma/surgery , Brain/diagnostic imaging , Brain/surgery , Child , Female , Humans , Magnetic Resonance Imaging , Male , Medulloblastoma/diagnostic imaging , Medulloblastoma/surgery , Neurosurgical Procedures , Odds Ratio , Postoperative Complications/diagnostic imaging , Retrospective Studies
20.
J Neurooncol ; 132(1): 155-162, 2017 03.
Article in English | MEDLINE | ID: mdl-28102486

ABSTRACT

While 2/3 of patients with ATRT are less than 3 years at diagnosis, the literature suggests younger children present with more aggressive disease and poorer outcome. However, little data exist on characteristics and outcome of patients diagnosed with ATRT in the first year of life. In particular, it is unclear whether they access similar treatments as do older children. We compared the cohort of patients ≤12 months from the Canadian ATRT registry to all cases extracted from the literature reported between 1996 and 2014 to describe their clinical and treatment characteristics, and potential prognostic factors. Twenty-six (33.7%) patients from the Canadian registry were ≤12 months at diagnosis as were 120 cases identified in the literature. Post-operatively, 46% of the registry's patients underwent palliation as opposed to 10.8% in the literature cohort. Palliative patients were significantly younger than those who received active therapy (3.3 vs. 6.6 months). While the use of high-dose chemotherapy (HDC) was relatively similar in both cohorts (42.9 and 35.5% respectively), radiotherapy (RT) use was significantly lower in the Canadian cohort (14.3 vs 44.9%). Children ≤6 months, who received active therapy, had a worst outcome than older ones. Gross total resection, HDC and adjuvant RT were associated with better outcomes. Eighty percent of the tested patients had evidence of germline mutation of INI1. While 1/3 of ATRT occurs within the first year of life, a large proportion only received palliative therapy. Even when actively treated, children ≤6 months fare worse. Some selected patients benefit from HDC.


Subject(s)
Rhabdoid Tumor/epidemiology , Teratoma/epidemiology , Canada , Female , Humans , Infant , Infant, Newborn , Kaplan-Meier Estimate , Male , Palliative Care/statistics & numerical data , Radiotherapy, Adjuvant , Registries , Rhabdoid Tumor/radiotherapy , Rhabdoid Tumor/surgery , Teratoma/radiotherapy , Teratoma/surgery , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL